How to Get Jatenzo in District of Columbia

What Jatenzo Is and Why It Matters for DC Patients

Jatenzo is the only FDA-approved oral testosterone therapy formulated as a self-emulsifying drug delivery system, allowing testosterone undecanoate to absorb through intestinal lymphatic channels rather than first-pass hepatic metabolism. The FDA granted approval in March 2019 for adult males with primary or hypogonadotropic hypogonadism [1]. Unlike older methyltestosterone tablets, Jatenzo does not carry a boxed warning for liver toxicity because it bypasses hepatic first-pass processing.

The key trial supporting approval, Swerdloff et al. published in the Journal of Clinical Endocrinology and Metabolism (2020), enrolled 166 hypogonadal men and demonstrated that 87% achieved average total testosterone concentrations within the normal range (300 to 1 to 000 ng/dL) at steady state [2]. Mean Cavg across the 24-hour dosing interval was 604 ng/dL. Blood pressure increases of roughly 3 to 5 mmHg systolic were observed, which is why Jatenzo's label carries a cardiovascular blood pressure warning and requires BP monitoring [1].

For DC patients specifically, this oral route removes the need for injections, gels, or patches, which can matter when living in smaller apartments, traveling frequently for federal-sector work, or managing needle-aversion. Twice-daily dosing with a meal fits predictably into a morning and evening routine.

Source: FDA Prescribing Information [1]

DC Prescribing Authority: Who Can Write the Prescription

In DC, testosterone is a Schedule III controlled substance under both federal law and the DC Uniform Controlled Substances Act. That classification determines which practitioners may prescribe it.

Physicians (MD/DO). Any DC-licensed physician with a valid DEA registration may prescribe Jatenzo. Endocrinologists, urologists, and primary care internists all qualify. The DC Board of Medicine licenses MDs and DOs through the Department of Licensing and Consumer Protection (DLCP) [3].

Nurse practitioners (APRN/NP). DC grants full practice authority to APRNs under DC Code Section 3-1206.04. A DC-licensed NP with an independent DEA registration may prescribe Schedule III controlled substances without physician supervision [4]. This is a meaningful access point: DC's full practice authority means telehealth NP-led TRT clinics can legally initiate and manage Jatenzo therapy without a collaborating physician agreement.

Physician assistants (PA). DC PAs hold dependent prescriptive authority and require a supervising physician agreement. A DC-licensed PA with a DEA registration may prescribe Schedule III substances, including testosterone, within the scope of that supervision agreement [5]. Most TRT-focused telehealth platforms employ MDs who serve as supervising physicians, satisfying this requirement.

Regardless of prescriber type, a new Jatenzo prescription requires a documented diagnosis of hypogonadism. That diagnosis must rest on laboratory evidence, not symptoms alone [6].

DC Board of Medicine [3] | DC APRN Practice Authority [4]

Required Labs Before a DC Prescriber Can Write Jatenzo

The Endocrine Society's 2018 Clinical Practice Guideline on testosterone therapy recommends confirming low testosterone on at least two separate morning blood draws before initiating treatment [6]. Most DC-licensed prescribers and telehealth platforms follow this guideline as the minimum standard of care.

The standard pre-prescription lab panel for Jatenzo in DC includes:

1. Total testosterone (morning, fasting). Two draws on separate days before 10 AM. Values below 300 ng/dL on both draws satisfy the laboratory criterion for hypogonadism per Endocrine Society guidance [6].
2. LH and FSH. Differentiates primary from secondary hypogonadism, which affects insurance coding and sometimes treatment choice.
3. Complete blood count (CBC) with hematocrit. Baseline hematocrit above 50% is a relative contraindication. The Jatenzo label requires hematocrit monitoring because erythrocytosis is a known testosterone class effect [1].
4. PSA (prostate-specific antigen). Required in men over 40. Active or suspected prostate cancer is a contraindication [1].
5. Comprehensive metabolic panel (CMP) including liver function tests. Baseline LFTs are standard given that any hepatic enzyme elevation warrants re-evaluation.
6. Blood pressure measurement. Jatenzo's FDA label includes a warning for hypertension; baseline BP documentation is required before prescribing [1].

Telehealth platforms serving DC typically accept recent lab results (within 90 days) from LabCorp, Quest, or any CLIA-certified DC facility. If you have no recent labs, most platforms direct you to a local draw site before your physician review appointment.

Endocrine Society 2018 Testosterone Guideline [6]

Telehealth Access to Jatenzo in DC: What the Rules Allow

DC permits telehealth-initiated prescriptions for Schedule III controlled substances when a valid patient-provider relationship exists. Following the COVID-19 public health emergency, the DEA proposed new rules for telehealth prescribing of controlled substances. Under the DEA's 2024 telemedicine framework, a practitioner may prescribe Schedule III non-narcotic substances (testosterone qualifies as non-narcotic Schedule III) via audio-visual telehealth without a prior in-person visit if certain safeguards are met [7].

Those safeguards include identity verification, a synchronous audio-video consultation, documentation of clinical indication in a prescription management system, and transmission of the prescription to a DEA-registered pharmacy. Most established telehealth TRT platforms already meet these requirements.

Practically, the DC telehealth Jatenzo pathway looks like this:

• Order labs online or at a local draw site.
• Complete a synchronous video consultation with a DC-licensed prescriber.
• Receive an electronic prescription sent directly to a pharmacy licensed in DC or to a mail-order pharmacy licensed to ship into DC.
• Return for a six-week follow-up (telehealth permitted) to check total testosterone Cavg and titrate dose.

The Swerdloff 2020 trial used a similar titration schedule: starting dose 237 mg twice daily, with adjustment to 158 mg or 396 mg twice daily at week 6 based on testosterone Cavg [2]. Clinicians using that protocol see roughly 87% of patients reach the 300 to 1 to 000 ng/dL target range within 12 weeks [2].

DEA Telemedicine Prescribing Rules [7] | Swerdloff et al. 2020 [2]

How to Get a Jatenzo Prescription in DC: Step-by-Step

Getting from "I think I have low testosterone" to "I have Jatenzo in hand" in DC follows a predictable sequence.

Step 1. Symptom and eligibility screening (Day 1). Most telehealth platforms begin with an online intake covering symptoms (fatigue, low libido, reduced morning erections, decreased muscle mass, mood changes), medical history, and current medications. Jatenzo is contraindicated in men with breast or prostate cancer, untreated severe obstructive sleep apnea, hematocrit above 50%, or uncontrolled hypertension [1].

Step 2. Laboratory draw (Days 1 to 3). If you have no qualifying labs, book a draw at a DC LabCorp (multiple locations including 1145 19th St NW) or Quest location. Results typically return within 24 to 48 hours.

Step 3. Physician or NP video consultation (Days 3 to 5). A DC-licensed prescriber reviews your labs, history, and symptoms. If hypogonadism is confirmed and no contraindications exist, the prescriber documents the diagnosis and writes the initial Jatenzo prescription at 237 mg twice daily.

Step 4. Pharmacy dispensing (Days 5 to 14). The prescription is transmitted electronically. DC pharmacies and licensed mail-order pharmacies ship Jatenzo within 2 to 7 business days depending on your insurance status and whether prior authorization is needed.

Step 5. Six-week follow-up (Week 6 to 7). A follow-up testosterone draw is required 6 hours after the morning dose (Jatenzo Cmax typically occurs at 4 to 5 hours post-dose [1]). The prescriber adjusts dose based on Cavg calculated from this draw.

Step 6. Ongoing monitoring (every 3 to 6 months). Hematocrit, PSA, blood pressure, and symptom review every 3 to 6 months per Endocrine Society guidelines [6].

DC Pharmacies and Mail-Order Options for Jatenzo

Jatenzo is a branded FDA-approved drug manufactured by Tolmar. It is dispensed through retail and mail-order pharmacies, not compounding pharmacies, unless a prescriber specifically orders compounded oral testosterone undecanoate under 503A rules.

Retail DC pharmacies. CVS, Walgreens, and several independent pharmacies in DC stock or can order Jatenzo. Because it is a specialty medication, smaller pharmacies may require 24 to 48 hours to obtain stock through their wholesaler.

Mail-order pharmacies. Insurance-affiliated mail-order pharmacies (CVS Caremark, OptumRx, Express Scripts) typically offer a 90-day supply at lower copay than retail. The prescription must be transmitted electronically from a DC-licensed provider or a telehealth provider with a valid DC prescribing authorization.

503A compounding pharmacies in DC. Under 21 U.S.C. 503A, a licensed DC compounding pharmacy may prepare oral testosterone undecanoate capsules when a prescriber determines the commercially available product does not meet an individual patient's clinical need (most commonly due to dose customization or excipient sensitivity) [8]. Compounded testosterone undecanoate is not interchangeable with Jatenzo and carries no FDA-approved labeling. DC's Board of Pharmacy oversees 503A compounders operating within the District.

Cash-pay cost. Without insurance, Jatenzo's retail price ranges from approximately $450 to $600 per month for the 237 mg twice-daily starting dose. Tolmar offers a savings card for commercially insured patients that may reduce out-of-pocket cost to $0 to $75 per month for eligible patients.

FDA 503A Compounding Overview [8]

DC Medicaid and Prior Authorization for Jatenzo

DC Medicaid (administered through the Department of Health Care Finance) covers Jatenzo for male hypogonadism but requires prior authorization (PA). Understanding what the PA process demands saves significant time.

Standard PA documentation required in DC:

• Two morning total testosterone lab results below 300 ng/dL on separate days, dated within the past 12 months.
• LH and FSH results documenting primary or secondary hypogonadism.
• Diagnosis code: ICD-10 E29.1 (testicular hypofunction) or E23.0 (hypopituitarism) for secondary cases.
• Documentation of clinical symptoms consistent with hypogonadism.
• Prescriber attestation that the patient has a contraindication to, or has failed or is unable to use, a lower-cost testosterone formulation (gel or injection), or a clinical justification for Jatenzo specifically (for example, needle aversion, occupational barrier to topical application, or documented tolerance issue with prior therapy).
• Blood pressure documentation showing BP is adequately controlled, given Jatenzo's labeled cardiovascular warning [1].

PA approvals in DC Medicaid typically take 3 to 10 business days. Expedited PA (24 to 72 hours) is available when the prescriber documents urgent clinical need. If the PA is denied, the prescriber may file a formal appeal citing the Endocrine Society guideline recommendation [6] and the clinical evidence from Swerdloff et al. [2].

Commercial insurers in DC (CareFirst BlueCross BlueShield, Aetna, UnitedHealthcare) each maintain their own formulary tier for Jatenzo. Most place it on Tier 3 or Tier 4, requiring PA with similar documentation requirements.

FDA Jatenzo Prescribing Information [1]

Transferring a Jatenzo Prescription to DC

If you are relocating to DC or establishing care with a new DC provider while already on Jatenzo therapy, the transfer process is straightforward but has one key constraint: because testosterone is Schedule III, DC pharmacies cannot accept a prescription written by an out-of-state prescriber unless that prescriber holds an active DC controlled-substance license or the prescription is being filled during a short-term DC visit under interstate recognition rules.

The practical path for relocation:

1. Request records (labs, titration history, current dose) from your previous provider.
2. Schedule a telehealth or in-person consultation with a DC-licensed prescriber.
3. The DC prescriber reviews your prior documentation, may order a new testosterone draw to establish a DC-based baseline, and issues a new DC prescription.

If your previous telehealth platform employs DC-licensed providers (many national platforms do), they can often write a new DC prescription at the same visit without requiring additional labs if your prior draws are within 90 days and within Endocrine Society testing standards [6].

DC does not have a specific grace period for out-of-state Schedule III prescriptions beyond the standard 30-day federal travel accommodation. Plan the transition before your existing supply runs out.

Monitoring Protocol After Starting Jatenzo in DC

Ongoing monitoring is not optional. The Jatenzo label specifies follow-up testosterone testing at week 6, and the Endocrine Society guideline recommends monitoring hematocrit, PSA, and symptoms at 3 months, then every 6 to 12 months [6].

The key monitoring parameters and their clinical thresholds:

• Testosterone Cavg. Target 300 to 1 to 000 ng/dL. Draw 6 hours after the morning dose at week 6 to calculate Cavg. If Cavg exceeds 1 to 000 ng/dL, reduce dose to 158 mg twice daily. If below 300 ng/dL, increase to 396 mg twice daily [1].
• Hematocrit. If hematocrit rises above 54%, hold Jatenzo until it falls below 50%, then restart at a lower dose or consider dose-reduction [1]. The Endocrine Society flags hematocrit above 54% as a threshold for dose interruption [6].
• Blood pressure. The TRAVERSE trial (N=5,246), a cardiovascular outcomes trial for testosterone therapy, found that testosterone did not significantly increase the rate of major adverse cardiovascular events (MACE) versus placebo (hazard ratio 1.02 to 95% CI 0.86 to 1.23) but did show higher rates of atrial fibrillation, acute kidney injury, and pulmonary embolism in the testosterone arm [9]. DC prescribers should document BP at every monitoring visit.
• PSA. Any PSA rise of more than 1.4 ng/mL above baseline within the first year, or PSA above 4.0 ng/mL at any point, warrants urology referral before continuing Jatenzo [6].

TRAVERSE Trial [9] | Endocrine Society Guideline [6]

Jatenzo vs. Other TRT Options Available in DC

DC patients have access to the full range of testosterone formulations. Choosing Jatenzo over alternatives involves specific clinical trade-offs.

Jatenzo vs. testosterone cypionate injection (generic). Testosterone cypionate 200 mg/mL costs roughly $30 to $80 per month and is generic. Jatenzo costs $450 to $600 per month cash pay. The injection produces a supraphysiologic peak followed by a trough, while Jatenzo produces a flatter PK profile with Cavg in the normal range [2]. Patients who prefer to avoid injections or who have occupational restrictions on injectable drug storage often prefer oral therapy.

Jatenzo vs. testosterone gels (AndroGel, Testim, Vogelxo). Transference risk to partners or children is a documented concern with topical testosterone [10]. Jatenzo eliminates transference risk entirely. The FDA issued a drug safety communication in 2009 regarding secondary testosterone exposure from gels, particularly to children [10].

Jatenzo vs. testosterone pellets. Pellets require in-office subcutaneous insertion every 3 to 6 months. Several DC-area urology and men's health practices perform pellet insertion. Pellets offer convenience from a dosing frequency standpoint but cannot be removed if side effects develop. Jatenzo can be discontinued immediately.

Jatenzo vs. clomiphene citrate (off-label). Some DC prescribers use clomiphene (50 mg daily or 25 mg daily) off-label for secondary hypogonadism in men who wish to preserve fertility. Clomiphene stimulates endogenous testosterone production and does not suppress spermatogenesis, while exogenous testosterone (including Jatenzo) suppresses LH and FSH and impairs sperm production [6]. Men with fertility goals should discuss this with their prescriber before starting any exogenous testosterone.

FDA Topical Testosterone Safety Communication [10]

HealthRX DC Access Framework: Matching Patient Profile to Pathway

Not every DC patient reaches Jatenzo through the same route. The table below maps the four most common patient profiles to the fastest appropriate pathway.

Profile A: No prior TRT, no insurance. Order labs at a DC Quest or LabCorp draw site, complete a telehealth consult with a DC-licensed provider on a cash-pay TRT platform, receive a Jatenzo prescription, and use the Tolmar savings card. Time to first dose: 5 to 10 days.

Profile B: No prior TRT, DC Medicaid. Complete labs at a DC FQHC or community health center (Unity Health Care has multiple DC locations), see a DC Medicaid-enrolled primary care physician or endocrinologist (in-person or telehealth), initiate PA process, and expect 7 to 14 days from PA submission to pharmacy fill.

Profile C: Prior TRT out of state, relocating to DC. Transfer records to a DC-licensed telehealth provider, obtain a bridge 30-day supply while PA is processed if switching to commercial insurance, and establish DC-based monitoring labs within 90 days of relocation.

Profile D: Existing DC patient seeking to switch from gel or injection. Document reason for switch (transference concern, injection site reactions, preference) in the chart note. This documentation supports the PA requirement for commercial insurers who want evidence of prior therapy.

Staying Current: DC Regulatory and Telehealth Changes to Watch

DC's telehealth regulations follow federal DEA scheduling decisions more closely than most states because DC is a federal district. The DEA's 2024 telemedicine special registration framework, if finalized as proposed, would create a permanent pathway for telehealth prescribing of Schedule III controlled substances including testosterone without a prior in-person visit [7]. Patients and providers should monitor DEA rulemaking through 2025 and 2026, as finalization will directly affect whether DC-based telehealth platforms can continue uninterrupted Jatenzo initiation services.

DC's Department of Health periodically updates its APRN and PA prescribing regulations. Any change to NP independent prescribing authority or PA supervision requirements would affect which telehealth platforms can independently prescribe Jatenzo in the District.

The American Urological Association's 2023 guidelines on testosterone deficiency define hypogonadism as total testosterone below 300 ng/dL with symptoms, aligning with the Endocrine Society threshold and reinforcing the two-draw requirement as standard of care [11]. DC prescribers following either guideline satisfy the clinical documentation burden for insurance PA and professional liability purposes.

AUA 2023 Testosterone Deficiency Guidelines [11] | Endocrine Society Guideline [6]